Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported third-quarter 2026 net product revenue of approximately $17.2 million, a more than fivefold increase from $3.3 million in the prior-year period, according to the company’s latest financial results. The surge was driven primarily by TONMYA, the company’s flagship fibromyalgia treatment, which contributed $15 million in revenue, representing a 37% increase over the second quarter. Total prescriptions rose 28% quarter over quarter to 16,375, with new prescriptions up 17% and refills climbing 56%. TONMYA coverage expanded to approximately 166 million lives, and Tonix increased its sales force to about 150 representatives to support the drug’s commercial trajectory.
The revenue growth matters because it signals that TONMYA, the first new treatment for fibromyalgia in more than 15 years, is gaining commercial traction. For a company that reported a net loss available to common stockholders of $53.3 million, or $2.89 per share, compared with a loss of $32 million, or $3.59 per share, a year earlier, the top-line expansion is critical. Tonix ended the quarter with approximately $163 million in cash and cash equivalents and expects its resources, together with approximately $1.5 million in subsequent equity financing proceeds, to fund operations into early third-quarter 2027. That extended runway gives the company room to continue advancing its clinical pipeline without immediate financing pressure.
Beyond the commercial results, Tonix is progressing several clinical programs. The company is conducting the Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, the planned Phase 2 TRAIL study of TNX-4800 for Lyme disease prevention, and an investigator-initiated Phase 2 study of TNX-1500 for kidney transplant rejection prevention. The latter two studies are expected to begin in the first quarter of 2027, with the TNX-4800 study pending final U.S. Food and Drug Administration agreement on its protocol. These pipeline efforts, if successful, could diversify Tonix’s revenue base beyond TONMYA and its acute migraine products, Zembrace SymTouch and Tosymra.
Investors seeking more detail on the quarterly results can view the full press release at https://ibn.fm/xRQdn. The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.
The announcement was distributed through TinyGems, a communications platform focused on small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. For full terms and disclaimers, see https://www.TinyGems.com/Disclaimer.
